MX2022016032A - Agonistas dobles de glp-1/gip de accion prolongada. - Google Patents
Agonistas dobles de glp-1/gip de accion prolongada.Info
- Publication number
- MX2022016032A MX2022016032A MX2022016032A MX2022016032A MX2022016032A MX 2022016032 A MX2022016032 A MX 2022016032A MX 2022016032 A MX2022016032 A MX 2022016032A MX 2022016032 A MX2022016032 A MX 2022016032A MX 2022016032 A MX2022016032 A MX 2022016032A
- Authority
- MX
- Mexico
- Prior art keywords
- long acting
- dual agonists
- acting glp
- gip
- gip dual
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a polipéptidos de acción prolongada agonistas del péptido 1 similar al glucagón y del polipéptido insulinotrópico dependiente de glucosa (GIP) humano que pueden usarse para tratar la diabetes mellitus tipo 2 (T2D), la diabetes con obesidad, la obesidad y la hiperlipidemia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021026360 | 2020-06-22 | ||
| IN202121002838 | 2021-01-20 | ||
| PCT/IB2021/055457 WO2021260530A1 (en) | 2020-06-22 | 2021-06-21 | Long acting glp-1/gip dual agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016032A true MX2022016032A (es) | 2023-04-19 |
Family
ID=76891103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016032A MX2022016032A (es) | 2020-06-22 | 2021-06-21 | Agonistas dobles de glp-1/gip de accion prolongada. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230241178A1 (es) |
| EP (1) | EP4146248A1 (es) |
| JP (1) | JP2023530515A (es) |
| KR (1) | KR20230023658A (es) |
| CN (1) | CN115768460A (es) |
| AU (1) | AU2021296376A1 (es) |
| BR (1) | BR112022025615A2 (es) |
| CA (1) | CA3183358A1 (es) |
| CL (1) | CL2022003654A1 (es) |
| CO (1) | CO2022018464A2 (es) |
| EC (1) | ECSP22095556A (es) |
| IL (1) | IL299195A (es) |
| MX (1) | MX2022016032A (es) |
| PE (1) | PE20230861A1 (es) |
| TW (1) | TW202216746A (es) |
| WO (1) | WO2021260530A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202229323A (zh) * | 2020-10-17 | 2022-08-01 | 印度商太陽製藥工業有限公司 | 新型glp-1/gip雙重促效劑 |
| MX2023008330A (es) | 2021-01-20 | 2024-01-18 | Viking Therapeutics Inc | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. |
| WO2024098718A1 (zh) * | 2022-11-07 | 2024-05-16 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201815338T4 (tr) | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
| US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| HUE060135T2 (hu) * | 2018-04-05 | 2023-02-28 | Sun Pharmaceutical Ind Ltd | Új GLP-1 analógok |
| CA3107108A1 (en) | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Method of using a gip/glp1 co-agonist for diabetes |
| MY197569A (en) | 2018-07-23 | 2023-06-25 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
-
2021
- 2021-06-18 TW TW110122388A patent/TW202216746A/zh unknown
- 2021-06-21 JP JP2022578936A patent/JP2023530515A/ja active Pending
- 2021-06-21 MX MX2022016032A patent/MX2022016032A/es unknown
- 2021-06-21 IL IL299195A patent/IL299195A/en unknown
- 2021-06-21 CN CN202180042855.9A patent/CN115768460A/zh active Pending
- 2021-06-21 BR BR112022025615A patent/BR112022025615A2/pt unknown
- 2021-06-21 CA CA3183358A patent/CA3183358A1/en active Pending
- 2021-06-21 EP EP21740614.9A patent/EP4146248A1/en active Pending
- 2021-06-21 US US18/002,478 patent/US20230241178A1/en active Pending
- 2021-06-21 WO PCT/IB2021/055457 patent/WO2021260530A1/en active Application Filing
- 2021-06-21 PE PE2022002928A patent/PE20230861A1/es unknown
- 2021-06-21 AU AU2021296376A patent/AU2021296376A1/en active Pending
- 2021-06-21 KR KR1020227043963A patent/KR20230023658A/ko unknown
-
2022
- 2022-12-19 CL CL2022003654A patent/CL2022003654A1/es unknown
- 2022-12-19 EC ECSENADI202295556A patent/ECSP22095556A/es unknown
- 2022-12-20 CO CONC2022/0018464A patent/CO2022018464A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4146248A1 (en) | 2023-03-15 |
| BR112022025615A2 (pt) | 2023-01-17 |
| KR20230023658A (ko) | 2023-02-17 |
| AU2021296376A8 (en) | 2022-12-22 |
| CA3183358A1 (en) | 2021-12-30 |
| US20230241178A1 (en) | 2023-08-03 |
| CN115768460A (zh) | 2023-03-07 |
| AU2021296376A1 (en) | 2022-12-08 |
| WO2021260530A1 (en) | 2021-12-30 |
| CO2022018464A2 (es) | 2023-03-17 |
| IL299195A (en) | 2023-02-01 |
| ECSP22095556A (es) | 2023-01-31 |
| JP2023530515A (ja) | 2023-07-18 |
| PE20230861A1 (es) | 2023-05-30 |
| CL2022003654A1 (es) | 2023-08-04 |
| TW202216746A (zh) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002906A (es) | Agonistas duales glp-1/gip. | |
| MX2022016032A (es) | Agonistas dobles de glp-1/gip de accion prolongada. | |
| PH12017501252A1 (en) | Gip and glp-1 co-agonist compounds. | |
| MY197569A (en) | Gip/glp1 co-agonist compounds | |
| WO2004056317A8 (en) | Compositions for the treatment and prevention of nephropathy | |
| MX2019007584A (es) | Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada. | |
| EP2301962A3 (de) | Erfindung betreffend GLP-1 und Exendin | |
| AU2019378845A8 (en) | Combination treatment of NAFLD and NASH | |
| WO2010013012A3 (en) | Hypothermia inducing polypeptides and uses thereof | |
| MX2022014368A (es) | Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo. | |
| MX2022009149A (es) | Compuestos coagonistas de gip/glp1. | |
| EP4095149A4 (en) | TRIPLE AGONIST FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR, GLUCAGON RECEPTOR, AND GASTRIC INHIBITOR POLYPEPTIDE RECEPTOR | |
| MX2022007666A (es) | Analogos de incretina y sus usos. | |
| ECSP23019850A (es) | Agonistas duales glp-1/gip | |
| MX2022012708A (es) | Agonista doble de receptor de glp-1 y glucagon de larga accion. | |
| WO2023111278A3 (en) | Peptides triple agonists of gip, glp-1 and glp-2 |